Novavax | NVAX - Cash And Equivalent


Novavax reported $228.36M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Adma Biologics USD 138.15M 50.52M Mar/2026
Agenus USD 35M 32M Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
Cassava Sciences USD 86.57M 8.93M Mar/2026
Geron USD 68.9M 10.54M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
MannKind USD 52.83M 22.05M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Moderna USD 1.91B 687M Mar/2026
Novartis USD 9.56B 2.9B Sep/2025
Novavax USD 228.36M 12.27M Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
TG Therapeutics USD 442.21M 242.7M Mar/2026